secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2026-07-30T20:03:41+00:00
Accession:  0001093557-26-000142
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DexCom Q2 2026 revenue up 13% to $1.308B; raises FY2026 guidance
----------------------------------------------------------------

- Revenue $1.308B (+13% YoY); U.S. +11%, international +19% reported.
- GAAP EPS $0.64; non-GAAP EPS $0.70; GAAP operating margin 24.3% (+590 bps YoY).
- Raises FY2026 revenue guidance to $5.18-5.25B (11-13% growth); raises non-GAAP operating margin to ~23.5-24%.
- CONNECT trial shows CGM improves glucose control in type 2 diabetes not on insulin; Stelo app launched with AI insights.
- Cash $1.95B; revolving credit undrawn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/0001093557-26-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001093557-26-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer